^(68)Ga-FAPI在疾病诊疗中的应用

Application of ^(68)Ga-FAPI in disease diagnosis and treatment

应用PET/CT诊断技术对恶性肿瘤患者进行早期诊断对其预后评估尤为重要,18F-氟脱氧葡萄糖(FDG)是目前核医学PET/CT诊断中最常用的正电子显像剂,其在鉴别病灶的良恶性、恶性肿瘤治疗的疗效评估以及疾病的术前评估中具有极大优势,已成为临床诊断不可或缺的影像学辅助手段。但其应用也有不便之处(如对患者有血糖和空腹的要求)。此外,颅脑和胃肠道的生理性摄取可能也会不同程度地影响临床医师做出正确诊断。^(68)Ga标记的成纤维细胞激活蛋白抑制剂(FAPI)是一种以成纤维细胞激活蛋白为靶点的新型正电子显像剂,因其具有检查前患者无需禁食和静息等以及T/NT高等优势,已成为研究热点。笔者就^(68)Ga-FAPI的靶点作用机制及临床应用进行综述。

The application of PET/CT for early diagnosis of patients with malignant tumors is particularly important for their prognostic assessment.18F-fluorodeoxyglucose(FDG)is currently the most commonly used positron imaging agent of PET/CT in nuclear medicine.It has great advantages in the differentiation of benign and malignant lesions,evaluation of the curative effect of malignant tumor treatment,and the preoperative evaluation of diseases,thus becoming an indispensable imaging aid for clinical diagnosis.But its application also has some inconveniences,such as the requirements of blood glucose and fasting for patients.In addition,the physiological uptake of brain and gastrointestinal tract may also affect clinicians to make correct diagnosis in varying degrees.By contrast,^(68)Ga-labeled fibroblast activation protein inhibitor(FAPI)is a new type of positron imaging agent targeting fibroblast activation protein.Its high T/NT and no additional requirements like fasting or bed rest for patients make it a hit in the research field.This paper reviews the target mechanism and clinical application of ^(68)Ga-FAPI.